ecancermedicalscience

Review

Clinical significance of microRNA-200 and let-7 families expression assessment in patients with ovarian cancer

14 Jun 2021
Severyn Ferneza, Markiyan Fetsych, Roman Shuliak, Halyna Makukh, Natalia Volodko, Roman Yarema, Tara Fetsych

Ovarian cancer (OC) represents the most lethal malignancy in gynaecologic oncology practice and shows a high recurrence rate due to its early chemoresistance to first-line chemotherapy. Yet, timely selection of the correct treatment strategy is likely to prolong a patient’s survival. MicroRNAs (miRNAs) are a class of short non-coding RNAs responsible for the expression of 30%–60% of human genes. In numerous studies, miRNAs have been used to provide the overall prognosis for patients and analyse the process’s prevalence and responses to chemotherapy. In particular, miRNAs as markers for predicting the sensitivity of OC to platinum- and taxane-based chemotherapeutics can significantly improve the treatment efficacy. This article highlights two families of miRNAs: miR-200 and let-7, which are promising for further research on OC and its chemosensitivity.

Related Articles

Anass Baladi, Hassan Abdelilah Tafenzi, Fatim-Zahra Megzar, Ibrahima Kalil Cisse, Othmane Zouiten, Leila Afani, Ismail Essaadi, Mohammed El Fadli, Rhizlane Belbaraka
Mariana Carvalho Gouveia, Renata Colombo Bonadio, Felippe Lazar Neto, Maísa Maria Spagnol Trento, Mateus Trinconi Cunha, Mariana Scaranti
Shreekant Dadheech, Kaustubh Burde, Pariseema Dave, Ruchi Arora, Chetna Parekh
Kamboji Sharanya, Lulu Abdul khader, Fathima Shahama Oliyath Vazhayil, Ghazal Tansir, Vaishnavi Vishwas, Simran Kaur, Sameer Rastogi, Ratna Sharma